Dexcom G8
Dexcom
Dexcom's next-generation CGM platform, unveiled at the company's May 2026 Investor Day. It is built on a new silicon chip and an "adaptive accuracy" algorithm that reads extra signals to self-adapt to each body over time, in a housing about 50% smaller than the G7 with 15-day wear. It is not yet FDA submitted — Dexcom plans to file in 2027 for a launch in late 2027 or early 2028. No accuracy (MARD) figure has been published.
The scorecard
Designed for higher accuracy via a new silicon chip and "adaptive accuracy" that measures extra signals to cut outliers and end-of-wear drift — but no MARD has been disclosed and no clinical accuracy data are published yet.[3]
A next-generation sensing platform expected to track changing glucose well; interstitial lag is inherent to CGM and no specific lag figure has been released.[1]
Expected to continue Dexcom's broad integrated-CGM (iCGM) ecosystem across pumps, AID algorithms and apps, as with G6/G7 — though no pump partners are confirmed for G8 yet.[1]
15-day wear, which Dexcom says becomes the baseline for future products (matching the G7 15-Day platform), plus a 12-hour grace period.[1]
Factory-calibrated with no routine fingersticks expected, consistent with G7, layered with new user-specific self-adaptation over the wear period.[4]
Expected to carry Dexcom's configurable predictive low/high alerts and app ecosystem; G8-specific alert features are not yet detailed.[1]
About 50% smaller than G7 with a flatter, more rounded housing and a smaller adhesive — a meaningful comfort and discretion gain.[1]
Not at launch: a multi-analyte version is on the roadmap after the initial G8 — potassium first, then ketones — so continuous ketone sensing is a later step, not an initial feature.[3]
Not yet available or even FDA-submitted: Dexcom plans to file in 2027 with a launch targeted for late 2027 or early 2028, and an international launch around 2028.[2]
The full picture
The Dexcom G8 is the next major continuous glucose monitor (CGM) platform from Dexcom, unveiled at the company's Investor Day on 14 May 2026.1 Dexcom's CEO described it as a "completely new product platform" built on a redesigned silicon chip developed over roughly two decades.2 It is not yet FDA-cleared or even submitted — and there is no Dexcom G8 product page yet — so everything here is drawn from Dexcom's announcement and reputable coverage of it.34
What's new
The headline is "adaptive accuracy." Beyond glucose, G8's sensor measures additional signals that let its algorithm adapt to a person's physiology in real time, which Dexcom says reduces accuracy outliers and the end-of-wear drift that affects current sensors.13 The hardware is about 50% smaller than the G7, with a flatter, more rounded housing and a smaller adhesive, and uses 15-day wear as the baseline going forward.3
What is not confirmed
No accuracy figure (MARD) has been published — claims of a specific "8.1%" number circulating online trace only to non-credible, apparently AI-generated sources and should be treated as unverified.3 Continuous ketone sensing is not an initial feature: a multi-analyte version is planned after the first G8, starting with potassium (for kidney disease) and then ketones.1
Timing
Dexcom says it is working toward an FDA submission in 2027, which could support a US launch in late 2027 or early 2028, depending on regulatory review, with an international launch around 2028.34 Until then, Dexcom's shipping CGMs are the G7, G7 15-Day and Dexcom ONE+.3
References
-
Diabetech. Dexcom Unveils Smaller Dexcom G8 CGM with Adaptive Accuracy Tech — new silicon chip; measures additional signals to adapt to physiology; FDA submission expected 2027; multi-analyte potassium then ketones. https://www.diabetech.info/p/dexcom-unveils-smaller-dexcom-g8-cgm-with-adaptive-accuracy-tech ↩ ↩2 ↩3
-
Drug Delivery Business. Dexcom unveils next-gen G8 CGM — factory-calibrated; ~50% smaller; new platform; submissions planned 2027; ex-US launch 2028. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ ↩
-
Dexcom. Dexcom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day — G8 unveiled May 14, 2026; ~50% smaller than G7; 15-day baseline; new silicon chip; self-adapting to the body; submission targeted 2027; launch late 2027 / early 2028; multi-analyte roadmap. https://www.theglobeandmail.com/investing/markets/stocks/DXCM/pressreleases/1983715/dexcom-maps-g8-launch-coverage-expansion-and-double-digit-growth-at-investor-day/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
Medtech Insight (Citeline). Dexcom Targets Late 2027 G8 Launch as It Bets on Body-Adaptive CGM Technology. https://insights.citeline.com/medtech-insight/device-area/diabetic-care/dexcom-targets-late-2027-g8-launch-as-it-bets-on-body-adaptive-cgm-technology-IUHRDDD3YRGG3OARTJFNRFLSZY/ ↩ ↩2
Coming soon
ETA · FDA submission planned 2027; US launch targeted late 2027 – early 2028
- →FDA 510(k) submission (Dexcom's stated plan) · 2027
- →US launch, then international launch · late 2027 – 2028
- →Multi-analyte G8 versions after launch — potassium first, then ketones · after initial launch
Sources
- [1]Dexcom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day (G8 unveiled May 14, 2026; ~50% smaller than G7; 15-day baseline; new silicon chip; self-adapting to the body; submission targeted 2027; launch late 2027 / early 2028; multi-analyte roadmap) · manufacturer · 2026-05-16
- [2]Dexcom Targets Late 2027 G8 Launch as It Bets on Body-Adaptive CGM Technology — Medtech Insight (Citeline) · news · 2026-05-15
- [3]Dexcom Unveils Smaller Dexcom G8 CGM with Adaptive Accuracy Tech (new silicon chip; measures additional signals to adapt to physiology; FDA submission expected 2027; multi-analyte potassium then ketones) — Diabetech · news · 2026-05-14
- [4]Dexcom unveils next-gen G8 CGM (factory-calibrated; ~50% smaller; new platform; submissions planned 2027; ex-US launch 2028) — Drug Delivery Business · news · 2026-05-14